Roivant Sciences (ROIV) FCF Margin Growth (3y) (2023 - 2026)
Powered by 
Analysis
Roivant Sciences (ROIV) FCF Margin Growth (3y) (2023 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.56 Bn | 197.57 Bn | 7.24 Bn | -2,024.00 |
| 2 | Gilead Sciences | 181.34 Bn | 178.16 Bn | 6.22 Bn | 1,067.00 |
| 3 | Vertex Pharmaceuticals | 132.22 Bn | 124.37 Bn | 2.84 Bn | -1,272.00 |
| 4 | Regeneron Pharmaceuticals | 82.87 Bn | 74.88 Bn | 3.93 Bn | -2,228.00 |
| 5 | Argenx Se | 61.55 Bn | 56.37 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.32 Bn | 49.19 Bn | 52.00 Mn | -5,426.00 |
| 7 | Alnylam Pharmaceuticals | 34.32 Bn | 31.01 Bn | 992.69 Mn | 4,612.00 |
| 8 | Biogen | 31.24 Bn | 29.95 Bn | 1.96 Bn | -203.00 |
| 9 | Roivant Sciences | 30.17 Bn | 30.17 Bn | 1.16 Mn | -1.75 Mn |
| 10 | Insmed | 28.17 Bn | 27.01 Bn | 358.27 Mn | 14,060.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.75 Mn |
| Dec 31, 2025 | -834,734.00 |
| Sep 30, 2025 | -1.08 Mn |
| Jun 30, 2025 | -359,523.00 |
| Dec 31, 2024 | -194,646.00 |
| Sep 30, 2024 | -510,246.00 |
| Jun 30, 2024 | -57,014.00 |
| Dec 31, 2023 | 36,992.00 |
| Jun 30, 2023 | 591,549.00 |